文献速递胸部肿瘤

BRAF突变肺癌的PD-L1表达、肿瘤突变负荷、微卫星不稳定状态及免疫检查点抑制剂疗效

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
PubMed 文献 · J Thorac Oncol · 2018-04-30

结果显示两组客观缓解率分别为25%和33%(p=1.0),中位PFS分别为3.7个月和4.1个月(p=0.37),BRAF突变类型和PD-L1表达均未影响缓解概率/PFS;接受ICPi患者中位OS未达到,未接受者为21.1个月(p=0.018)。

要点

  • BRAF突变NSCLC中PD-L1高表达比例较高,TMB多为低/中水平,MSI多为稳定型。
  • ICPi在BRAF V600E和非V600E突变NSCLC中均显示一定活性,ORR分别为25%和33%。
  • BRAF突变类型和PD-L1表达未显著影响ICPi的缓解概率或PFS。

核心结论

  • BRAF突变NSCLC与PD-L1高表达、低/中TMB及微卫星稳定状态相关。
  • ICPi在BRAF V600E和非V600E突变NSCLC中均具有较好活性。

研究设计与样本

  • 多中心回顾性病历回顾,纳入39例BRAF突变NSCLC患者,分为V600E组(n=21)和非V600E组(n=18)。
  • PD-L1表达、TMB和MSI状态分别评估了29例(74%)、11例(28%)和12例(31%)患者。

主要发现

  • V600E组PD-L1高表达(≥50%)、中间(1-49%)、无表达(<1%)分别为8/19(42%)、6/19(32%)、5/19(26%);非V600E组分别为5/10(50%)、1/10(10%)、4/10(40%)。
  • V600E组2例肿瘤显示高TMB(25%),无MSI-H病例。
  • 中位PFS分别为3.7个月(95%CI 1.6-6.6)和4.1个月(95%CI 0.1-19.6)(log-rank检验=0.81,p=0.37)。
  • 接受ICPi者中位OS未达到(95%CI 13-NR),未接受者为21.1个月(95%CI 1.8-NR)(log-rank检验=5.58,p=0.018)。

临床怎么用

  • BRAF突变NSCLC患者可考虑使用免疫检查点抑制剂,无论V600E或非V600E突变类型。
  • PD-L1表达和BRAF突变亚型不宜单独用于筛选ICPi获益人群。

局限性

  • 回顾性研究,样本量小(39例),部分生物标志物数据缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The efficacy of immune checkpoint inhibitors (ICPi) in BRAF mutant NSCLC is unknown. METHODS: Multi-institutional retrospective chart review identified 39 patients with BRAF mutant NSCLC. The patients were divided into two groups: V600E (group A, n = 21) and non-V600E (group B, n = 18). Programmed death ligand 1 (PD-L1) expression, tumor mutational burden (TMB) and microsatellite instability status were assessed in 29 (74%), 11 (28%), and 12 (31%) patients, respectively. Objective response rate, progression-free survival (PFS) with ICPi, and overall survival were analyzed. RESULTS: High (≥50%), intermediate (1-49%), and no (<1%) PD-L1 expression was observed in 8 of 19 (42%), 6 of 19 (32%), 5 of 19 (26%), and 5 of 10 (50%), 1 of 10 (10%), and 4 of 10 (40%) cases in groups A and B, respectively. Two tumors in group A showed high TMB (25%); none were microsatellite instability status-high. Twenty-two patients (group A, n = 12; group B, n = 10) received ICPi. Objective response rate with ICPi was 25% and 33% in groups A and B, respectively (p = 1.0). Median PFS with ICPi was 3.7 months (95% confidence interval [CI]: 1.6-6.6), and 4.1 months (95% CI: 0.1-19.6) in groups A and B, respectively (log-rank test = 0.81, p = 0.37). Neither BRAF mutation type nor PD-L1 expression affected the response probability/PFS. Median overall survival was not reached (95% CI: 13-NR) and comprised 21.1 months (95% CI: 1.8-NR) for patients who were and were not exposed to ICPi, respectively (log-rank test = 5.58, p = 0.018). CONCLUSIONS: BRAF mutant NSCLC is associated with high level of PD-L1 expression, low/intermediate TMB and microsatellite-stable status. ICPi have favorable activity both in BRAF V600E and BRAF non-V600E mutant NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Dudnik E, Peled N, Nechushtan H, et al. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. J Thorac Oncol. 2018. PMID: 29723688. doi:10.1016/j.jtho.2018.04.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。